Online inquiry

IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5965MR)

This product GTTS-WQ5965MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5965MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ714MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ13874MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ5722MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ8141MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ2642MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ15414MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ14662MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ7595MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW